Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRB2 | P07550 | 19/20 | 0.62 |
| ▸ | ADRB3 | P13945 | 4/20 | 0.54 |
| ▸ | ADRB1 | P08588 | 3/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3624911 | 1.00 | ADRB2 (0.62) | ADRB2ADRB3ADRB1 | |
| SCHEMBL3624828 | 0.88 | ADRB2 (0.66) | ADRB2 | |
| SCHEMBL3658849 | 0.88 | ADRB2 (0.66) | ADRB2 | |
| SCHEMBL3624830 | 0.88 | ADRB2 (0.66) | ADRB2 | |
| SCHEMBL3620916 | 0.85 | ADRB2 (0.48) | ADRB2ADRB3ADRB1 | |
| SCHEMBL3620914 | 0.85 | ADRB2 (0.48) | ADRB2ADRB3ADRB1 | |
| SCHEMBL3625135 | 0.79 | ADRB2 (0.68) | ADRB2ADRB3ADRB1 | |
| SCHEMBL3625140 | 0.79 | ADRB2 (0.68) | ADRB2ADRB3ADRB1 | |
| SCHEMBL3619539 | 0.78 | ADRB2 (0.79) | ADRB2 | |
| SCHEMBL3619543 | 0.78 | ADRB2 (0.79) | ADRB2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1730103-B1 | FORMAMIDE DERIVATIVES USEFUL AS ADRENOCEPTOR | PFIZER LTD (GB) | 2010-05-26 | — | — | EP | claimed |
| EP-1730103-B1 | FORMAMIDE DERIVATIVES USEFUL AS ADRENOCEPTOR | PFIZER LTD (GB) | 2010-05-26 | — | — | EP | disclosed |
| US-7547731-B2 | Formamide derivatives for the treatment of diseases | PFIZER INC (US) | 2009-06-16 | — | — | US | disclosed |
| US-7241810-B2 | Formamide derivatives for the treatment of diseases | PFIZER INC (US) | 2007-07-10 | — | — | US | disclosed |
| EP-1730103-A1 | FORMAMIDE DERIVATIVES USEFUL AS ADRENOCEPTOR | Pfizer Limited (GB) | 2006-12-13 | — | — | EP | disclosed |
| WO-2005092840-A1 | FORMAMIDE DERIVATIVES USEFUL AS ADRENOCEPTOR | PFIZER LIMITED (GB) | 2005-10-06 | — | — | WO | disclosed |
| US-20050215590-A1 | Formamide derivatives for the treatment of diseases | PFIZER LIMITED (GB) | 2005-09-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050215590-A1 | Formamide derivatives for the treatment of diseases | FH, FAH, HRH4 | ADRB2 751/4885ADRB3 941/4885ADRB1 919/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.